atrasentan has been researched along with Embolism, Pulmonary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayach, B; Battistini, B; Blouin, A; Gosselin, M; Jeng, AY; Opgenorth, TJ; Tsang, J; Wang, FH; Wessale, J; Wu-Wong, JR | 1 |
| Alexiou, K; Baumann, G; Dschietzig, T; Laule, M; Schrör, K; Stangl, K | 1 |
2 other study(ies) available for atrasentan and Embolism, Pulmonary
| Article | Year |
|---|---|
Effects of a selective endothelin A receptor antagonist, ABT-627, in healthy normotensive anaesthetized rats developing acute pulmonary air embolism.
Topics: Acute Disease; Animals; Atrasentan; Embolism, Air; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-3; Gene Expression; Lung; Male; Models, Animal; Oxygen; Pulmonary Embolism; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin | 2002 |
Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunction.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Aspartic Acid Endopeptidases; Atrasentan; Coronary Circulation; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Endothelins; Endothelium, Vascular; Glycopeptides; In Vitro Techniques; Male; Metalloendopeptidases; Myocardial Contraction; Oligopeptides; Peptides, Cyclic; Protein Precursors; Pulmonary Embolism; Pyrrolidines; Rabbits; Thromboxane B2; Vasoconstriction | 1998 |